+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

M

Actively Recruiting

Researchers are evaluating the efficacy and safety of eloralintide in adults with moderate-to-severe obstructive sleep apnea OSA who are also obese or overweight. The study uses a master protocol called YDAO that includes two separate studies YSA1 for participants who cannot or do not want to use Positive Airway Pressure PAP therapy, and YSA2 for those who have been on PAP therapy for at least three months and plan to continue it during the study. The goal is to understand how eloralintide affects body weight and sleep apnea severity. Participants will be randomly assigned to receive either eloralintide or a placebo, both given as weekly subcutaneous injections. The study lasts about 76 weeks and includes two groups based on PAP therapy use. During the study, participants will continue their current PAP therapy status according to their assigned group. The study is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the study, participants will undergo assessments at baseline and Week 64, including measuring changes in body weight, apnea-hypopnea index AHI, blood pressure, triglycerides, sleep-related impairment, and other health markers. Researchers will also monitor safety, medication use, and pharmacokinetics. Participants can expect regular visits for evaluations and monitoring over the study period to understand the effects of eloralintide on OSA and obesity-related health factors.

Age: 18Years +All GendersPhase 3
115 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating how the body responds to empasiprubart when given using an autoinjector AI. This study focuses on understanding the effects, how empasiprubart works in the body, and its safety. The study involves healthy adult volunteers aged 18 to 65 and is sponsored by argenx. The study has two parts, A and B. In part A, participants are randomly assigned to receive empasiprubart as a subcutaneous injection via autoinjector in the abdomen, via autoinjector in the thigh, or as an intravenous infusion. In part B, participants are randomized to receive empasiprubart either by subcutaneous autoinjector in the abdomen or by intravenous infusion. The treatment periods last up to 37 weeks for part A and up to 43 weeks for part B. During the study, participants will undergo various assessments to monitor drug levels, body response, and safety. Researchers will measure how empasiprubart is absorbed and processed in the body, including specific outcomes such as drug concentration over time and immune responses. Safety will be monitored by tracking any adverse events. Participants will attend regular visits for evaluations throughout the study period.

Age: 18Years - 65YearsAll GendersPhase 1
1 location
S

Actively Recruiting

Researchers are studying the safety, tolerability, effectiveness, pharmacokinetics, and pharmacodynamics of ALN-2232 in adults with obesity. The study evaluates single ascending doses, multiple doses of ALN-2232 alone, and multiple doses of ALN-2232 combined with tirzepatide. This research aims to better understand how these treatments work and their effects on patients with obesity. Participants will be randomly assigned to receive either a single dose or multiple doses of ALN-2232 or placebo. Some will also receive tirzepatide once weekly alongside ALN-2232. All doses are given as injections under the skin. The study includes separate parts for each dosing regimen to assess safety and body weight changes over time. During the study, participants will have regular visits to monitor safety, body weight, and drug levels in their blood and urine. Researchers will measure adverse events up to 12 months and track changes in body weight and body composition up to 6 to 12 months. Laboratory tests and protein analyses in fat tissue will also be performed to understand treatment effects. The total participation duration may last up to one year.

Age: 18Years - 65YearsAll GendersPhase 1Phase 2
1 location
P

Actively Recruiting

Researchers are conducting a Phase 1, randomized, double-blind, placebo-controlled study to evaluate ALN-6222 in adults with obesity. The study focuses on assessing the safety, tolerability, how the drug moves and acts in the body, and its potential effects in participants with a body mass index between 30 and less than 40 kgm. This trial aims to gather important information about ALN-6222 as a treatment option for obesity. Participants will receive a single subcutaneous dose of either ALN-6222 or a placebo. The study uses a parallel design where participants are randomly assigned to one of these two groups. This single ascending dose study will monitor participants over time to observe how the drug behaves and its effects compared to placebo. During the study, participants will be monitored for adverse events for up to 12 months. Researchers will collect blood samples before dosing and up to three days after to measure drug levels and protein markers. Additional assessments of protein markers will continue for up to 12 months after dosing. This comprehensive monitoring helps evaluate the safety and biological impact of ALN-6222 throughout the study period.

Age: 18Years - 65YearsAll GendersPhase 1
1 location
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide at different dose levels compared to a placebo in adults with uncontrolled moderate to severe asthma. The study aims to understand how brenipatide impacts asthma control and exacerbation rates over time. This phase 2, randomized, double-blind trial involves participants aged 18 to 75 years who have a history of asthma and recent asthma exacerbations. Participants will receive either one of two doses of brenipatide or a placebo, all administered by subcutaneous injection. The treatment period lasts 52 weeks, during which the effects of the study drug on asthma symptoms and lung function will be monitored. The study includes screening, treatment, and follow-up phases, with the overall participation lasting about 65 weeks. During the trial, participants will undergo assessments such as lung function tests, health questionnaires, and monitoring for asthma exacerbations and medication use. Blood samples may be collected to study the drugs behavior in the body and the immune response. Researchers will track safety and treatment effects throughout the study and during follow-up to understand the long-term impact of brenipatide on asthma control.

Age: 18Years - 75YearsAll GendersPhase 2
119 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.

Age: 40Years - 80YearsAll GendersPhase 3
305 locations
R

Actively Recruiting

Healthy Volunteer

Researchers are studying how two different forms of the medicine elinzanetant are absorbed and processed in healthy women aged 18 to 65 years. The goal is to compare a new tablet form with an existing capsule form to understand any differences in how the body handles these two versions. This study focuses on managing hot flush symptoms related to changes in female hormones. Participants will receive both forms of elinzanetant in a randomized sequence during two treatment periods. Each treatment is taken orally once daily for 10 days within each 12-day period. The study uses a crossover design, meaning each participant receives both treatments at different times, allowing comparison within the same individual. During the study, participants will take the medicine under controlled conditions at a study center, and blood samples will be collected on specific days to measure how the drug is absorbed and processed. Researchers will monitor plasma drug levels and record any treatment-emergent side effects. The entire participation duration covers the two treatment periods with assessments on multiple days to evaluate drug levels and safety.

Age: 18Years - 65YearsFEMALEPhase 1
1 location
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating SAB01, an investigational bispecific monoclonal antibody targeting mast cells, in a first-in-human Phase 1 clinical trial involving healthy adult participants. The study aims to assess the safety, pharmacokinetics, and pharmacodynamics of single ascending doses of SAB01 administered subcutaneously and intravenously. This randomized, double-blind, placebo-controlled study includes up to 88 participants across planned and optional cohorts monitored by a Safety Review Committee. Participants receive a single dose of SAB01 or placebo via subcutaneous injection or intravenous infusion. The study has 7 planned cohorts for subcutaneous and intravenous administration and up to 4 optional cohorts based on emerging safety and pharmacological data. Dose levels for intravenous administration will not exceed those evaluated by subcutaneous injection. Participants are randomized in a 62 ratio to receive SAB01 or placebo within each cohort. During the study, participants undergo safety and tolerability assessments from Day 1 through Day 113, alongside evaluations of SAB01s plasma pharmacokinetic profile and pharmacodynamic effects. Researchers monitor bioavailability, clearance rates, volume of distribution, half-life, and immunogenicity. Participants are required to comply with all study procedures and are monitored with laboratory tests, physical examinations, and electrocardiograms to ensure health status throughout the study period.

Age: 18Years - 55YearsAll GendersPhase 1
2 locations